BYM704 - CONTROLLED RELEASE and TARGETTING TECHNIQUES
| Course Name | Code | Semester | Theory (hours/week) |
Application (hours/week) |
Credit | ECTS |
|---|---|---|---|---|---|---|
| CONTROLLED RELEASE and TARGETTING TECHNIQUES | BYM704 | Any Semester/Year | 3 | 0 | 3 | 9 |
| Prequisites | - | |||||
| Course language | Turkish | |||||
| Course type | Elective | |||||
| Mode of Delivery | Face-to-Face | |||||
| Learning and teaching strategies | Lecture Discussion Question and Answer | |||||
| Instructor (s) | Assoc. Prof. Dr. Ä°pek EroÄŸlu | |||||
| Course objective | The aim of the course is make an introduction for the controlled release dosage forms, which were formulated to overcome the disadvantages of the conventional dosage forms and to maintain the required knowledge accumulation. | |||||
| Learning outcomes |
| |||||
| Course Content | - Clarification and documentation of the disadvantages of drug delivery with conventional dosage forms and identification of controlled release dosage forms, comparison and evaluation of the advantages and disadvantages. - Investigation on the drug delivery (active and passive targeting) and release mechanisms of the controlled release dosage forms. - Detailed evaluation and classification of the site of action and administration of the controlled release dosage forms. - Introduction of the new generation and futuristic status of controlled release dosage forms from the perspective of novel technological improvements. - Current status of controlled release dosage forms in the Turkish and worldwide markets. | |||||
| References | - Devarajan P.D., Jain S., Targeted Drug Delivery : Concepts and Design, Springer, 2015. - Senyigit, T., Ozcan, I., Ozer, O., Nanotechnology in Progress: Pharmaceutical Applications, Kerala-India, Research Signpost, 2012. - Siepmann J., Siegel R.A., Rathbone M.J., Fundamentals and Applications of Controlled Release Drug Delivery, Springer, 2012. - De Villiers M.M., Aramwit P., Kwon G.S., Nanotechnology in Drug Delivery, AAPS Springer, 2009. - Marx U., Sandig V., Drug Testing In Vitro, WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim, 2007. - Maskevich B.O., Drug Delivery Research Advances, Nova Science Publishers, Inc. New York, 2007. - Li X., Bhaskara R. Jasti B.R., Design of Controlled Release Drug Delivery Systems, McGraw-Hill Co., New York, 2006. - Uchegbu I. F., Polymers in Drug Delivery, CRC Press 2006. - Hillery A.M., Llyod A.W., Swarbrick J., Drug Delivery and Targetting for Pharmacists and Pharmaceutical Scientists, Taylor & Francis, 2005. | |||||
Course outline weekly
| Weeks | Topics |
|---|---|
| Week 1 | General information about the active pharmaceutical ingredient (API), excipients and pharmaceutical products |
| Week 2 | Definition of controlled release dosage forms and comparison with the conventional dosage forms (advantages/disadvantages) |
| Week 3 | R&D, P&D studies, production of controlled release formulations in the pharmaceutical industry and good manufacturing practices (GMP) |
| Week 4 | Characterization, stability, efficacy and quality control of the controlled release dosage forms |
| Week 5 | Particular and vesicular controlled release dosage forms (micro/nanocapsules, micro/nanospheres, solid lipid nanoparticles, liposomes) |
| Week 6 | Classification of controlled release dosage forms with respect to the release mechanism of the active ingredient |
| Week 7 | Classification of controlled release dosage forms with respect to site or route of administration: Oral, buccal, ocular and nasal systems |
| Week 8 | Classification of controlled release dosage forms with respect to site or route of administration: Transdermal systems |
| Week 9 | Classification of controlled release dosage forms with respect to site or route of administration: Vaginal, rectal and colonic drug delivery systems |
| Week 10 | MIDTERM EXAM |
| Week 11 | Targeting of the controlled release dosage forms (active and passive targeting) |
| Week 12 | Current and future applications of controlled release dosage forms (gene/drug/combination therapies) (General overview of the TUBITAK project calls) Medicines and Medical Devices Agency) |
| Week 13 | Controlled release systems ? patent evaluations |
| Week 14 | Controlled release dosage forms that are currently available in the Turkish and worldwide markets (TITCK, FDA and EMA perspectives) |
| Week 15 | Discussion and paper presentations |
| Week 16 | FINAL EXAM |
Assesment methods
| Course activities | Number | Percentage |
|---|---|---|
| Attendance | 0 | 0 |
| Laboratory | 0 | 0 |
| Application | 0 | 0 |
| Field activities | 0 | 0 |
| Specific practical training | 0 | 0 |
| Assignments | 0 | 0 |
| Presentation | 1 | 20 |
| Project | 0 | 0 |
| Seminar | 0 | 0 |
| Midterms | 1 | 30 |
| Final exam | 1 | 50 |
| Total | 100 | |
| Percentage of semester activities contributing grade succes | 1 | 50 |
| Percentage of final exam contributing grade succes | 1 | 50 |
| Total | 100 | |
WORKLOAD AND ECTS CALCULATION
| Activities | Number | Duration (hour) | Total Work Load |
|---|---|---|---|
| Course Duration (x14) | 14 | 3 | 42 |
| Laboratory | 0 | 0 | 0 |
| Application | 0 | 0 | 0 |
| Specific practical training | 0 | 0 | 0 |
| Field activities | 0 | 0 | 0 |
| Study Hours Out of Class (Preliminary work, reinforcement, ect) | 14 | 7 | 98 |
| Presentation / Seminar Preparation | 1 | 40 | 40 |
| Project | 0 | 0 | 0 |
| Homework assignment | 0 | 0 | 0 |
| Midterms (Study duration) | 1 | 40 | 40 |
| Final Exam (Study duration) | 1 | 50 | 50 |
| Total Workload | 31 | 140 | 270 |
Matrix Of The Course Learning Outcomes Versus Program Outcomes
| D.9. Key Learning Outcomes | Contrubition level* | ||||
|---|---|---|---|---|---|
| 1 | 2 | 3 | 4 | 5 | |
| 1. Ability to understand and implement pure sciences, mathematics and engineering in higher level, | X | ||||
| 2. Ability to conduct intra- and inter-disciplinary studies; to gain required methodological skills for conducting the research, | X | ||||
| 3. Ability to analyse, synthesize and evaluate the current ideas and developments in the specialized area, | X | ||||
| 4. To have a qualification to conduct a comprehensive research that bringing new insights into science and technology, that leading to a novel methodology or technological product/process; or that leveraging a known methodology to another area, | X | ||||
| 5. To contribute to the scientific and technological literature by disseminating the outcomes of scientific studies in international and national academic grounds, | X | ||||
| 6. To evaluate the scientific, technological and social developments and to transfer them to the society by considering scientific neutrality and ethical responsibility, | X | ||||
| 7. Ability to have a verbal and written communication skills in at least one foreign language at a European Language Portfolio C1 General Level, | X | ||||
| 8. Ability to understand theeffects of engineering solutions and practice in the problems related to the biological systems and to build awareness of the legal outcomes. | X | ||||
*1 Lowest, 2 Low, 3 Average, 4 High, 5 Highest